■ Iridex Corporation, a provider of ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, has entered into a strategic collaboration with Topcon Corporation. The transaction nets $19.5 million of cash to Iridex, providing multiyear funding for strategic growth initiatives, particularly those designed to drive expanded market penetration of Iridex’s unique nonincisional glaucoma therapy products. Topcon invests in Iridex by purchasing exclusive rights to distribute Iridex’s retina and glaucoma products in certain global markets, and acquiring a common equity stake of approximately 10.4% in Iridex.